Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Sirio Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Sirio Pharma has a total shareholder equity of CN¥2.5B and total debt of CN¥1.2B, which brings its debt-to-equity ratio to 47.2%. Its total assets and total liabilities are CN¥5.2B and CN¥2.7B respectively. Sirio Pharma's EBIT is CN¥455.6M making its interest coverage ratio 5.3. It has cash and short-term investments of CN¥585.5M.

Anahtar bilgiler

47.2%

Borç/özkaynak oranı

CN¥1.18b

Borç

Faiz karşılama oranı	5.3x
Nakit	CN¥585.53m
Eşitlik	CN¥2.49b
Toplam yükümlülükler	CN¥2.68b
Toplam varlıklar	CN¥5.17b

Son finansal sağlık güncellemeleri

Recent updates

The Market Lifts Sirio Pharma Co., Ltd. (SZSE:300791) Shares 27% But It Can Do More

Sep 30

Is Sirio Pharma (SZSE:300791) Using Too Much Debt?

Sep 23

Sirio Pharma Co., Ltd.'s (SZSE:300791) Prospects Need A Boost To Lift Shares

Aug 01

Sirio Pharma (SZSE:300791) Will Be Hoping To Turn Its Returns On Capital Around

Jun 30

Is Sirio Pharma (SZSE:300791) A Risky Investment?

Jun 12

An Intrinsic Calculation For Sirio Pharma Co., Ltd. (SZSE:300791) Suggests It's 24% Undervalued

Apr 24

Sirio Pharma (SZSE:300791) Seems To Use Debt Quite Sensibly

Mar 06

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 300791's short term assets (CN¥1.9B) exceed its short term liabilities (CN¥751.4M).

Uzun Vadeli Yükümlülükler: 300791's short term assets (CN¥1.9B) do not cover its long term liabilities (CN¥1.9B).

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 300791's net debt to equity ratio (23.7%) is considered satisfactory.

Borcun Azaltılması: 300791's debt to equity ratio has increased from 24.4% to 47.2% over the past 5 years.

Borç Kapsamı: 300791's debt is well covered by operating cash flow (30.7%).

Faiz Kapsamı: 300791's interest payments on its debt are well covered by EBIT (5.3x coverage).

Sirio Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Sirio Pharma (SZSE:300791) Using Too Much Debt?

Is Sirio Pharma (SZSE:300791) A Risky Investment?

Sirio Pharma (SZSE:300791) Seems To Use Debt Quite Sensibly

Recent updates

The Market Lifts Sirio Pharma Co., Ltd. (SZSE:300791) Shares 27% But It Can Do More

Sirio Pharma Co., Ltd. to Report Q3, 2024 Results on Oct 24, 2024

Investor sentiment improves as stock rises 29%

Is Sirio Pharma (SZSE:300791) Using Too Much Debt?

Price target decreased by 7.2% to CN¥29.75

Second quarter 2024 earnings released: EPS: CN¥0.74 (vs CN¥0.30 in 2Q 2023)

Sirio Pharma Co., Ltd.'s (SZSE:300791) Prospects Need A Boost To Lift Shares

Now 21% overvalued

Now 21% overvalued

Sirio Pharma (SZSE:300791) Will Be Hoping To Turn Its Returns On Capital Around

Sirio Pharma Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024

Investor sentiment deteriorates as stock falls 27%

Is Sirio Pharma (SZSE:300791) A Risky Investment?

Price target increased by 7.8% to CN¥41.67

An Intrinsic Calculation For Sirio Pharma Co., Ltd. (SZSE:300791) Suggests It's 24% Undervalued

Sirio Pharma Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Sirio Pharma (SZSE:300791) Seems To Use Debt Quite Sensibly

Sirio Pharma Co., Ltd. to Report Fiscal Year 2023 Results on Apr 22, 2024

Third quarter 2023 earnings released: EPS: CN¥0.47 (vs CN¥0.37 in 3Q 2022)

Investor sentiment improves as stock rises 17%

Consensus revenue estimates increase by 12%, EPS downgraded

Second quarter 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.54 in 2Q 2022)

Sirio Pharma Co., Ltd. to Report First Half, 2023 Results on Aug 25, 2023

Sirio Pharma Co., Ltd. Announces Implementation of Cash Dividend for the Year 2022, Payable on June 07, 2023

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.37 (vs CN¥0.30 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.54 (vs CN¥0.49 in 2Q 2021)

Now 22% undervalued

Now 23% undervalued

Now 20% undervalued

Sirio Pharma Co., Ltd. announced that it expects to receive CNY 1.35 billion in funding

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Sirio Pharma Co., Ltd. Announces Final Profit Distribution Plan for 2021 on A Shares, Payable on 23 May 2022

Less than half of directors are independent

Sirio Pharma Co., Ltd., Annual General Meeting, May 05, 2022

Now 23% undervalued after recent price drop

Sirio Pharma Co., Ltd. Announces the Profit Distribution Proposal for 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.34 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.49 (vs CN¥0.41 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Sirio Pharma Co., Ltd. Approves Final Divided for 2020

Sirio Pharma Co., Ltd. Proposes Final Dividend for the Year 2020

Full year 2020 earnings released: EPS CN¥2.14 (vs CN¥1.46 in FY 2019)

New 90-day low: CN¥83.31

Investor sentiment deteriorated over the past week

New 90-day high: CN¥113

Investor sentiment improved over the past week

New 90-day low: CN¥84.38

New 90-day low: CN¥86.60

Third quarter earnings released

Market bids up stock over the past week

New 90-day high - CN¥116

Earnings released

Sirio Pharma Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

New 90-day high - CN¥89.00

Sirio Pharma Co., Ltd. announced a financing transaction

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin